GlaxoSmithKline (GB:GSK) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
GSK’s latest trial results reveal that Blenrep, in combination with other drugs, significantly reduces the risk of death in multiple myeloma patients by 42% compared to the standard treatment. These findings highlight Blenrep’s potential to become a new standard of care, with regulatory reviews underway in major markets. Investors might find GSK’s advancements in this treatment promising for the company’s growth and stock performance.
For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.
